BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29383678)

  • 1. Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.
    Grozinsky-Glasberg S; Kaltsas G; Kaltsatou M; Lev-Cohain N; Klimov A; Vergadis V; Uri I; Bloom AI; Gross DJ
    Endocrine; 2018 Jun; 60(3):499-509. PubMed ID: 29383678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors.
    Fiore F; Del Prete M; Franco R; Marotta V; Ramundo V; Marciello F; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A
    Endocrine; 2014 Sep; 47(1):177-82. PubMed ID: 24385266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
    Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
    HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
    Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
    Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes.
    Pericleous M; Caplin ME; Tsochatzis E; Yu D; Morgan-Rowe L; Toumpanakis C
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):61-9. PubMed ID: 26663886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transarterial embolizations in metastatic neuroendocrine tumors.
    de Mestier L; Zappa M; Hentic O; Vilgrain V; Ruszniewski P
    Rev Endocr Metab Disord; 2017 Dec; 18(4):459-471. PubMed ID: 28975561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
    Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
    Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
    Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
    AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution.
    Engelman ES; Leon-Ferre R; Naraev BG; Sharma N; Sun S; O'Dorisio TM; Howe J; Button A; Zamba G; Halfdanarson TR
    Pancreas; 2014 Mar; 43(2):219-25. PubMed ID: 24518499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.
    de Baere T; Deschamps F; Tselikas L; Ducreux M; Planchard D; Pearson E; Berdelou A; Leboulleux S; Elias D; Baudin E
    Eur J Endocrinol; 2015 Apr; 172(4):R151-66. PubMed ID: 25385817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial liver-directed therapies of neuroendocrine hepatic metastases.
    Nazario J; Gupta S
    Semin Oncol; 2010 Apr; 37(2):118-26. PubMed ID: 20494704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of hepatic trans-arterial chemoembolization in metastatic medullary thyroid carcinoma: a specialist center experience and review of the literature.
    Grozinsky-Glasberg S; Bloom AI; Lev-Cohain N; Klimov A; Besiso H; Gross DJ
    Eur J Endocrinol; 2017 Apr; 176(4):463-470. PubMed ID: 28100632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arterial embolization of hepatic metastases from neuroendocrine tumors].
    Libicher M; Bovenschulte H
    Radiologe; 2009 Mar; 49(3):233-41. PubMed ID: 19183927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study.
    Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S
    J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemoperfusion and embolization in the treatment of liver metastases].
    Vogl TJ; Mack MG; Eichler K; Zangos S; Naguib NN; Gruber-Rouh T
    Rofo; 2011 Jan; 183(1):12-23. PubMed ID: 21113865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.